Kirkland & Ellis advised Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, on its agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion. Completion of the transaction is subject to customary closing conditions and regulatory approvals. Closing is expected to occur during the fourth quarter of 2019.
Read the company press release
The Kirkland team was led by transactional partners David Feirstein and James Hu along with David Fox, debt finance partner Melissa Hutson, executive compensation partner Scott Price and antitrust and competition partners Ian John and Paula Riedel. The Cambrex Corporation in-house legal team was led by Samantha Hanley, Senior Vice President, General Counsel and Secretary and Peter Heller, Senior Corporate Counsel and Assistant Corporate Secretary.